50 years old is rare, and when it does occur it usually points to a predisposing factor, as in this case, where a brain metastasis led to the formation of a hematoma (GelabertGonzález et al., 2012) .
Moreover, while the radiological image of the patient in their study shows a hematoma, it is of small and therefore leads one to question how this can be responsible for such a midline shift. This suggests that something more must be involved, as was revealed at autopsy where a metastases was identified.
In a recent paper, Kruijff and Hoekstra (2012) state that the protein S-100B is probably the best biomarker for melanoma, having potential to identify high-risk stage III melanoma patients who may benefit from adjuvant systematic treatment. Since an effective (adjuvant) therapy for locoregional metastatic and disseminated melanoma has only been recently introduced, the diagnostic of S-100B, they argue, is set to increase in the near future.
It therefore appears inappropriate to consider differential levels of S-100B as indicative of the evolution of CSH, as suggested by the paper's title, since they can be more indicative of a melanoma and its metastasis.
A commentary on
Case report: extreme levels of serum S-100B in a patient with chronic subdural hematoma by Persson M. E., Thelin E. P., and Bellander B. M. (2012) Front. Neurol. 3:170. doi: 10.3389/ fneur.2012.00170 We are surprised by the conclusions of a recent paper by Persson et al. (2012) , "Case report: extreme levels of serum S-100B in a patient with chronic subdural hematoma," which suggest that S-100B protein is an important marker for chronic subdural hematoma (CSDH). In our opinion, and that of other authors, S-100B is a significant marker of multiple neurological pathologies.
Chronic subdural hematoma is a relatively common complication, especially among the elderly, where the incidence is estimated as 7.4/100,000. Two circumstances account for its high incidence among the elderly; the extensive brain atrophy often found in the elderly or alcoholics, and long-term use anticoagulant (Gelabert et al., 2001) . CSDH in patients less than
